WESTPORT, Conn., Aug. 25, 2011 /PRNewswire/ -- Advanced BioHealing, Inc. (ABH), a leader in commercializing regenerative medicine therapies, today announced that it ranked in the top 200 (No. 187) on this year's Inc. 500 list of America's fastest-growing, privately held companies.
Inc. magazine's annual list provides the most comprehensive look at a vital segment of the U.S. economyAmerica's independent-minded entrepreneurs. ABH increased revenue from zero in 2006 to $146 million in 2010 and by year-end employed more than 300 professionals. It is this success that led to the recent acquisition of ABH by Shire plc, the global specialty biopharmaceutical company. The acquisition combines ABH's experience and commercial capability in regenerative medicine with Shire's expertise in developing and commercializing products targeting unmet medical needs, and in human cell biological manufacturing.
"This recognition reflects the hard work and dedication of the extraordinarily talented team here at ABH," said Kevin Rakin, CEO. "Since 2006, we have built a fully integrated, profitable regenerative medicine company marketing Dermagraft, an FDA-approved living cell therapy with a dedicated sales force, scalable cell-based manufacturing, and established reimbursement."
About Advanced BioHealing, Inc.
Advanced BioHealing (ABH), a Shire company, specializes in the development and commercialization of life-altering regenerative medicine therapies. ABH currently manufactures and markets Dermagraft®, a bio-engineered skin substitute approved by the FDA for the treatment of diabetic foot ulcers, that assists in restoring damaged tissue and supports the body's natural healing process. The Company maintains its corporate office in Westport, Conn. with additional sites in La Jolla, Calif. and Nashville, Tenn. To learn more about ABH, please visit the Company's web site at www.ABH.com.
Direct: (615) 250-3311
Cell: (206) 335-0114
Direct: (323) 202-1424
Cell: (415) 819-2214
SOURCE Advanced BioHealing, Inc.